A Phase 1 Study of Eribulin Mesylate (E7389; IND #116;292); A Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (Excluding CNS); Including Lymphomas: A Participation Limited to the COG Phase 1 Consortium